Literature DB >> 31373701

Reduction in Drinking was Associated With Improved Clinical Outcomes in Women With HIV Infection and Unhealthy Alcohol Use: Results From a Randomized Clinical Trial of Oral Naltrexone Versus Placebo.

Robert L Cook1, Zhi Zhou1, Maria Jose Miguez2, Clery Quiros2, Luis Espinoza3, John E Lewis4, Babette Brumback5, Kendall Bryant6.   

Abstract

BACKGROUND: Alcohol consumption is associated with poor health outcomes in women living with HIV (WLWH), but whether medication can help to reduce drinking in non-treatment-seeking women or whether reduction in drinking improves HIV outcomes is unclear. We conducted a randomized clinical trial (RCT) of daily oral naltrexone (50 mg) versus placebo in WLWH who met criteria for current unhealthy alcohol use.
METHODS: WLWH with current unhealthy alcohol use (>7 drinks/wk or >3 drinks/occasion) were randomly assigned to daily oral naltrexone 50 mg (n = 96) or placebo (n = 98) for 4 months. Drinking outcomes, including the proportion of women who reduced (<unhealthy use criteria) or quit drinking, were assessed at baseline, 2 months, 4 months (end of treatment), and 7 months. In a secondary analysis, HIV viral suppression and changes in CD4 counts were compared in women who did or did not reduce/quit drinking, regardless of intervention assignment.
RESULTS: The participants' mean age was 48 years, 86% were African American, and 94% were receiving HIV antiretroviral therapy. Among all participants, 89% and 85% completed the 4-month and 7-month follow-ups, respectively. Participants in both groups substantially reduced drinking over time. At 1 and 3 months, naltrexone was associated with a greater reduction in drinking (p < 0.05), but the proportion who reduced/quit drinking at 4 months (52% vs. 45%, p = 0.36) or 7 months (64% in both groups) was not different. HIV viral suppression at follow-up was significantly better in participants who reduced/quit drinking versus those continuing unhealthy alcohol use at 4 months (72% vs. 53%, p = 0.02) and 7 months (74% vs. 54%, p = 0.02).
CONCLUSIONS: Participating in an RCT to reduce drinking was associated with significant drinking reduction regardless of medication assignment, suggesting that nonmedication aspects of research study participation (e.g., repeated assessments and support from research staff) could be important interventions to help reduce drinking outside of research studies. Drinking reduction was associated with improved HIV viral suppression, providing evidence to support recommendations to avoid unhealthy alcohol use among WLWH.
© 2019 The Authors. Alcoholism: Clinical & Experimental Research published by Wiley Periodicals, Inc. on behalf of Research Society on Alcoholism.

Entities:  

Keywords:  Alcohol Consumption; HIV Infection; Pharmacotherapy; Randomized Clinical Trial; Women

Year:  2019        PMID: 31373701      PMCID: PMC6684328          DOI: 10.1111/acer.14130

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  43 in total

1.  PHosphatidylethanol (PEth) concentrations in blood are correlated to reported alcohol intake in alcohol-dependent patients.

Authors:  Steina Aradottir; Gulber Asanovska; Stefan Gjerss; Per Hansson; Christer Alling
Journal:  Alcohol Alcohol       Date:  2006-04-19       Impact factor: 2.826

2.  Variable selection for propensity score models.

Authors:  M Alan Brookhart; Sebastian Schneeweiss; Kenneth J Rothman; Robert J Glynn; Jerry Avorn; Til Stürmer
Journal:  Am J Epidemiol       Date:  2006-04-19       Impact factor: 4.897

3.  Alcohol consumption, ART usage and high-risk sex among women infected with HIV.

Authors:  K P Theall; R A Clark; A Powell; H Smith; P Kissinger
Journal:  AIDS Behav       Date:  2007-03

Review 4.  Challenges and successes in linking HIV-infected women to care in the United States.

Authors:  Mariam Aziz; Kimberly Y Smith
Journal:  Clin Infect Dis       Date:  2011-01-15       Impact factor: 9.079

Review 5.  Biological, clinical, and ethical advances of placebo effects.

Authors:  Damien G Finniss; Ted J Kaptchuk; Franklin Miller; Fabrizio Benedetti
Journal:  Lancet       Date:  2010-02-20       Impact factor: 79.321

6.  The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field.

Authors:  Bankole A Johnson; Nassima Ait-Daoud; John D Roache
Journal:  J Stud Alcohol Suppl       Date:  2005-07

Review 7.  Alcohol and HIV disease progression: weighing the evidence.

Authors:  Judith A Hahn; Jeffrey H Samet
Journal:  Curr HIV/AIDS Rep       Date:  2010-11       Impact factor: 5.071

8.  Naltrexone for the treatment of alcohol dependence among African Americans: results from the COMBINE Study.

Authors:  Lara A Ray; David W Oslin
Journal:  Drug Alcohol Depend       Date:  2009-08-29       Impact factor: 4.492

9.  Erectile dysfunction drug receipt, risky sexual behavior and sexually transmitted diseases in HIV-infected and HIV-uninfected men.

Authors:  Robert L Cook; Kathleen A McGinnis; Jeffrey H Samet; David A Fiellin; Maria C Rodriguez-Barradas; Maria C Rodriquez-Barradas; Kevin L Kraemer; Cynthia L Gibert; R Scott Braithwaite; Joseph L Goulet; Kristin Mattocks; Stephen Crystal; Adam J Gordon; Krisann K Oursler; Amy C Justice
Journal:  J Gen Intern Med       Date:  2009-11-18       Impact factor: 5.128

10.  Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment.

Authors:  Jennifer W Tidey; Peter M Monti; Damaris J Rohsenow; Chad J Gwaltney; Robert Miranda; John E McGeary; James MacKillop; Robert M Swift; David B Abrams; Saul Shiffman; Jean A Paty
Journal:  Alcohol Clin Exp Res       Date:  2007-11-20       Impact factor: 3.455

View more
  9 in total

1.  Changes in Days of Unhealthy Alcohol Use and Antiretroviral Therapy Adherence, HIV RNA Levels, and Condomless Sex: A Secondary Analysis of Clinical Trial Data.

Authors:  Derek D Satre; Varada Sarovar; Wendy Leyden; Charles B Hare; Sheryl L Catz; Kendall J Bryant; Emily C Williams; J Carlo Hojilla; Michael A Horberg; Michael J Silverberg
Journal:  AIDS Behav       Date:  2020-06

2.  Characterizing Unhealthy Alcohol Use Patterns and Their Association with Alcohol Use Reduction and Alcohol Use Disorder During Follow-Up in HIV Care.

Authors:  Thibaut Davy-Mendez; Varada Sarovar; Tory Levine-Hall; Alexandra N Lea; Stacy A Sterling; Felicia W Chi; Vanessa A Palzes; Mitchell N Luu; Jason A Flamm; C Bradley Hare; Emily C Williams; Kendall J Bryant; Constance M Weisner; Michael J Silverberg; Derek D Satre
Journal:  AIDS Behav       Date:  2022-09-28

3.  Negative Consequences of Alcohol Use among People Living with HIV.

Authors:  Rebecca J Fisk; Veronica L Richards; Robert F Leeman; Babette Brumback; Christa Cook; Robert L Cook
Journal:  Subst Use Misuse       Date:  2021-03-26       Impact factor: 2.164

4.  Neuroimaging and Cognitive Evidence for Combined HIV-Alcohol Effects on the Central Nervous System: A Review.

Authors:  Mark K Britton; Eric C Porges; Vaughn Bryant; Ronald A Cohen
Journal:  Alcohol Clin Exp Res       Date:  2020-12-30       Impact factor: 3.928

Review 5.  Contribution of Behavioral Health Factors to Non-AIDS-Related Comorbidities: an Updated Review.

Authors:  Natalie E Chichetto; Brittanny M Polanka; Kaku A So-Armah; Minhee Sung; Jesse C Stewart; John R Koethe; E Jennifer Edelman; Hilary A Tindle; Matthew S Freiberg
Journal:  Curr HIV/AIDS Rep       Date:  2020-08       Impact factor: 5.495

6.  The Relationship of Alcohol to ART Adherence Among Black MSM in the U.S.: Is it Any Different Among Black MSM in the South?

Authors:  Shantrel S Canidate; Eric W Schrimshaw; Nancy Schaefer; Nioud Mulugeta Gebru; Noelani Powers; Stephen Maisto; Christina Parisi; Robert F Leeman; Sheldon Fields; Robert L Cook
Journal:  AIDS Behav       Date:  2021-11-06

7.  Secondary Analysis of a Randomized Clinical Trial of Naltrexone Among Women Living With HIV: Correlations Between Reductions in Self-Reported Alcohol Use and Changes in Phosphatidylethanol.

Authors:  Veronica L Richards; Ruba Sajdeya; Karina Villalba; Yan Wang; Vaughn Bryant; Babette Brumback; Kendall Bryant; Judith A Hahn; Robert L Cook
Journal:  Alcohol Clin Exp Res       Date:  2020-12-17       Impact factor: 3.455

8.  Impact of Reduction in Drinking vs. complete Cessation on the Severity and Type of Alcohol-Related Problems in Women Living with HIV.

Authors:  Veronica L Richards; Zhi Zhou; Yan Wang; Krishna Vaddiparti; Babette Brumback; Robert L Cook
Journal:  Subst Use Misuse       Date:  2021-03-08       Impact factor: 2.164

9.  Recruitment, experience, and retention among women with HIV and hazardous drinking participating in a clinical trial.

Authors:  Shantrel S Canidate; Christa L Cook; Deepthi Varma; Giselle D Carnaby; Nicole Ennis; Nichole E Stetten; Robert L Cook
Journal:  BMC Public Health       Date:  2020-07-27       Impact factor: 4.135

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.